Zinetac Tablets (Generic Ranitidine Hydrochloride Tablets)

Zinetac Tablets (Generic Ranitidine Hydrochloride Tablets)
© The Swiss Pharmacy

Zinetac (Generic Ranitidine Hydrochloride tablets)
relieves heartburn associated with acid indigestion and
sour stomach. This medicine also prevents heartburn
associated with acid indigestion and sour stomach
brought on by certain foods and beverages.
This medicine is also used for the treatment of
gastroesophageal reflux disease (GERD) in patients with
less severe GERD.

Zinetac Tablets are manufactured by GlaxoSmithKline
Pharmaceuticals Limited, India in the strengths of 150 mg and
300 mg.

Chemical Structure

The active ingredient contained in Zinetac tablets is
Ranitidine Hydrochloride.
Each Zinetac tablet contains Ranitidine Hydrochloride
equivalent to 150 mg or 300 mg of Ranitidine.

Uses of Zinetac 150mg and 300mg Tablets:
Zinetac Tablets (Generic Ranitidine Hydrochloride Tablets) is used to
treat ulcers of the stomach and intestines and prevent them from
coming back after they have healed. This medication is also used to
treat certain stomach and throat (esophagus) problems (such as
erosive esophagitis, gastroesophageal reflux disease-GERD, Zollinger-
Ellison syndrome). It works by decreasing the amount of acid your
stomach makes. It relieves symptoms such as cough that doesn't go
away, stomach pain, heartburn, and difficulty swallowing. Ranitidine
belongs to a class of drugs known as H2 blockers. This medication is
also available without a prescription. It is used to prevent and treat
heartburn and other symptoms caused by too much acid in the
stomach (acid indigestion).
URL: https://www.theswisspharmacy.com/product_info.php?info=p9628_Ranitidine-Hydrochloride-Tablets.html

Zinetac (Generic Ranitidine tablets) are used for the treatment of
duodenal ulcer and benign gastric ulcer, including that associated with
non-steroidal anti-inflammatory agents. They are also used for the
following:
Treatment of duodenal ulcers associated with Helicobacter pylori
infection.
Treatment of post-operative ulcer
Zollinger-Ellison syndrome
Oesophageal reflux disease
Chronic episodic dyspepsia, characterised by pain (epigastric or
retrosternal) which is related to meals or disturbs sleep but is not
associated with the preceding conditions may benefit from Ranitidine
Hydrochloride treatment.

Zinetac Tablets are indicated for the following conditions where
reduction of gastric secretion and acid output is desirable:
prophylaxis of gastrointestinal haemorrhage from stress
ulceration in seriously ill patients
prophylaxis of recurrent haemorrhage in patients with bleeding
peptic ulcers before general anaesthesia in patients considered
to be at risk of acid aspiration (Mendelson's syndrome),
particularly obstetric patients during labour.

Recommended Adult Dosage
The recommended adult oral dosage of Zinetac Tablets (Generic
Ranitidine tablets) for duodenal ulcer is 150 mg twice daily. An
alternative dosage of 300 mg once daily after the evening meal or at
bedtime can be used for patients in whom dosing convenience is
important.
The recommended adult dosage for maintenance of healing of
duodenal ulcers is 150 mg at bedtime.
The recommended adult dosage for pathological hypersecretory
conditions (such as Zollinger-Ellison syndrome) is 150 mg twice a day.

Recommended Adult Dosage
GERD: The current recommended adult oral dosage is 150 mg
twice a day.
Erosive Esophagitis: The current recommended adult oral
dosage is 150 mg four times a day.
Maintenance of Healing of Erosive Esophagitis: The current
recommended adult oral dosage is 150 mg twice a day.

Contraindications
➔
Zinetac is contraindicated in patients with a known
hypersensitivity to Ranitidine Hydrochloride or any
component of the tablet.

Storage Instructions
Zinetac Tablets (Generic Ranitidine Hydrochloride
Tablets) have to be stored at controlled room
temperature i.e. from 20°C to 25°C (68°F to 77°F) with
excursions permitted between 15° to 30°C (59° to
86°F).
Keep this as well as all other medicines away from
children and pets.

Warnings
The possibility of malignancy should be excluded before commencement of
therapy in patients with gastric ulcer and in patients of middle age and over
with new or recently changed dyspeptic symptoms as treatment with
Ranitidine may mask symptoms of gastric carcinoma.
Ranitidine is excreted via the kidney and so plasma levels of the medication
are increased in patients with renal impairment. The dose should be adjusted
in patients with renal impairment.
Regular supervision of patients who are taking non-steroidal anti-
inflammatory drugs concomitantly with Zinetac tablets is recommended,
especially in the elderly. Current evidence shows that ranitidine protects
against NSAID associated ulceration in the duodenum and not in the stomach.

Warnings
Rare reports suggest that Ranitidine Hydrochloride may precipitate
acute porphyric attacks in patients with acute porphyria. Zinetac
tablets should therefore be avoided in patients with a history of acute
porphyria.
In patients such as the elderly, persons with chronic lung disease,
diabetes or the immunocompromised, there may be an increased risk
of developing community acquired pneumonia.
The prolonged use of H2-receptor antagonists, may impair the
absorption of protein-bound Vitamin B12 and may contribute to the
development of Cyanocobalamin (vitamin B12) deficiency.

Zinetac Tablets and Alcohol
It is best not to mix Zantac and alcohol. It is possible for most people to
take Zantac with small amounts of alcohol safely, but it could be
dangerous. The dangers of mixing Zinetac and alcohol include
increased effect of alcohol. However, avoid consuming alcohol as it is
known to increase acidity and can make your acidity worse.

Possible Side Effects
The following side effects have been reported as events in clinical trials or in
the routine management of patients treated with Ranitidine Hydrochloride
(Zinetac tablets).
Central nervous system: Rarely, malaise, dizziness, somnolence, insomnia and
vertigo. Rare cases of reversible mental confusion, depression and
hallucinations have been reported, predominantly in severely ill and elderly
patients. In addition reversible involuntary movement disorders have been
reported rarely. There have been a few reports of reversible blurred vision
suggestive of a change in accommodation. Reversible impotence has been
reported rarely.
Cardiovascular: As with other H2-receptor antagonists, rare reports of
tachycardia, bradycardia, premature ventricular beats, atrioventricular block
and asystole.
Gastrointestinal: Constipation, diarrhoea, nausea/vomiting, abdominal
discomfort/pain.

Hepatic: Transient and reversible changes in liver-function tests can occur.
There have been occasional reports of hepatitis, hepatocellular or
hepatocanalicular or mixed, with or without jaundice. These were usually
reversible.
Renal: Very rare cases of acute interstitial nephritis have been reported.
Musculoskeletal: Rare reports of arthralgias and myalgia.
Haematological: Rare reports of agranulocytosis or pancytopenia,
sometimes with marrow hypoplasia or aplasia, have been reported. Blood
count changes (leucopenia, thrombocytopenia) have occurred in a few
patients. These are usually reversible.
Dermatological: Rash, including rare cases of mild erythema multiforme.
Rare cases of vasculitis and alopecia have been reported.

Endocrine: Controlled studies in animals and humans have shown no
stimulation of any pituitary hormone by Ranitidine (Zinetac tablets), no
antiandrogenic activity, and cimetidine induced gynaecomastia and
impotence in hypersecretory patients have resolved when ranitidine was
substituted. However, occasional cases of breast conditions such as
gynaecomastia and galactorrheoa, impotence and loss of libido have been
reported in male patients receiving Ranitidine, but the incidence did not
differ from that in the general population.
Other: Rare cases of hypersensitivity reactions (e.g. fever, bronchospasm,
anaphylactic shock, rash, eosinophilia, urticaria, angioneurotic oedema,
hypotension, chest pain, rash, eosinophilia), small increases in serum
creatinine. Acute pancreatitis has been reported rarely.

Zinetac Tablets Overdosage
There has been limited experience with Ranitidine Hydrochloride
(Zinetac tablets) overdosage.
Reported acute ingestions of up to 18 g orally have been associated
with transient adverse effects similar to those encountered in normal
clinical experience. In addition, abnormalities of gait and hypotension
have been reported.
When overdosage occurs, the usual measures to remove unabsorbed
material from the gastrointestinal tract, clinical monitoring, and
supportive therapy should be employed.

Zinetac Tablets During Pregnancy
Ranitidine Hydrochloride (Zinetac tablets) has been classified by the
US FDA as Pregnancy Category B.
Reproduction studies have been performed in rats and rabbits at oral
doses up to 160 times the human oral dose and have revealed no
evidence of impaired fertility or harm to the fetus due to Ranitidine.
There are, however, no adequate and well-controlled studies in
pregnant women.
Because animal reproduction studies are not always predictive of
human response, this medicine should be used during pregnancy only
if clearly needed.

Zinetac Tablets (Generic Ranitidine Hydrochloride
Tablets) are manufactured by GlaxoSmithKline
Pharmaceuticals Limited, India.

Zinetac Tablets (Generic Ranitidine Hydrochloride Tablets)

More Related Content

Similar to Zinetac Tablets (Generic Ranitidine Hydrochloride Tablets)

More from The Swiss Pharmacy

Recently uploaded

Zinetac Tablets (Generic Ranitidine Hydrochloride Tablets)